Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Neuren Pharmaceuticals Limited ( (AU:NEU) ).
Neuren Pharmaceuticals reported strong momentum in Q1 2026 via partner Acadia, with DAYBUE net sales rising 20% year-on-year to US$101 million and Neuren’s related royalties increasing 23% to US$10.4 million, while full-year DAYBUE sales guidance of US$460–490 million and expected royalties of US$50–54 million were maintained. A limited U.S. launch of the new DAYBUE STIX powder formulation generated more than 250 prescriptions and over 80% caregiver satisfaction, while an expert panel recommended DAYBUE as part of standard care for eligible Rett syndrome patients and the accelerated Japan trial plus ongoing European review underscore the drug’s expanding global footprint.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$19.10 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on developing therapies for serious neurological disorders, including rare pediatric conditions. Its primary commercial asset is trofinetide, marketed in the U.S. as DAYBUE for Rett syndrome through a partnership with Acadia Pharmaceuticals, with additional development underway in Japan and regulatory processes ongoing in Europe.
Average Trading Volume: 487,204
Technical Sentiment Signal: Sell
Current Market Cap: A$1.59B
Learn more about NEU stock on TipRanks’ Stock Analysis page.